Novoa-Bolivar Erika M, Ros José A, Pérez-Fernández Sonia, Campillo José A, López-Hernández Ruth, González-López Rosana, Otálora-Alcaraz Almudena, Ortuño-Hernández Cristina, Gimeno Lourdes, Ruiz-Lorente Inmaculada, Ceballos-Francisco Diana, Muro Manuel, Solana Elena, Martinez-Camblor Pablo, Minguela Alfredo
Immunology Service, Clinical University Hospital Virgen de la Arrixaca (HCUVA), Biomedical Research Institute of Murcia Pascual Parrilla (IMIB), 30120 Murcia, Spain.
Pneumology Service, Clinical University Hospital Virgen de la Arrixaca (HCUVA), Biomedical Research Institute of Murcia Pascual Parrilla (IMIB), 30120 Murcia, Spain.
Cells. 2024 Dec 13;13(24):2066. doi: 10.3390/cells13242066.
Interstitial lung diseases (ILDs) are pathologies affecting the pulmonary interstitium and, less frequently, the alveolar and vascular epithelia. Bronchoalveolar lavage (BAL) is commonly used in ILD evaluation since it allows the sampling of the lower respiratory tract. The prognostic value of BAL cell counts in ILD is unknown. Flow cytometry quantification of lymphocytes and neutrophils in BAL of 1074 real-life consecutive patients were retrospectively correlated with clinical, radiological, anatomopathological, functional/spirometry, and evolutionary data. Cut-offs with predictive value were established at 7% and 5% for lymphocytes and neutrophils, respectively. Three risk stratification groups (Risk-LN) were established: FAVORABLE (lymphocytes > 7% and neutrophils < 5%), INTERMEDIATE (rest of patients), and UNFAVORABLE (lymphocytes < 7% and neutrophils > 5%), showing 75th percentile overall survival (OS) of 10.0 ± 1.4, 5.8 ± 0.6, and 3.0 ± 0.3 years ( < 0.001), respectively. A scoring model combining Risk-LN and the age of the patients with great predictive capacity for OS on fibrotic and non-fibrotic ILDs is proposed. This score is an independent predictive factor (HR = 1.859, = 0.002) complementary to the fibrosis status (HR = 2.081, < 0.001) and the type of treatment. Flow cytometry of BAL provides rapid and accurate quantification of lymphocytes and neutrophils, allowing the establishment of a risk score model that is useful in the clinical management of fibrotic and non-fibrotic ILDs from the time of diagnosis.
间质性肺疾病(ILDs)是影响肺间质的病理状况,较少情况下也会影响肺泡和血管上皮。支气管肺泡灌洗(BAL)常用于ILD评估,因为它能对下呼吸道进行采样。BAL细胞计数在ILD中的预后价值尚不清楚。对1074例连续真实病例的BAL中淋巴细胞和中性粒细胞进行流式细胞术定量分析,并回顾性地将其与临床、放射学、解剖病理学、功能/肺量计以及病情演变数据相关联。淋巴细胞和中性粒细胞的预测值临界值分别设定为7%和5%。建立了三个风险分层组(Risk-LN):有利组(淋巴细胞>7%且中性粒细胞<5%)、中间组(其余患者)和不利组(淋巴细胞<7%且中性粒细胞>5%),其总体生存率(OS)的第75百分位数分别为10.0±1.4年、5.8±0.6年和3.0±0.3年(<0.001)。提出了一种结合Risk-LN和患者年龄的评分模型,该模型对纤维化和非纤维化ILD的OS具有很强的预测能力。该评分是一个独立的预测因素(HR = 1.859, = 0.002),是对纤维化状态(HR = 2.081,<0.001)和治疗类型的补充。BAL的流式细胞术可快速准确地定量淋巴细胞和中性粒细胞,从而建立一个风险评分模型,该模型从诊断时起就有助于纤维化和非纤维化ILD的临床管理。